Neola Medical (NEOLA.ST) Osake Kurssi

Neola Medical AB commercializes medical devices based on its patented GASMAS technology for continuous lung monitoring in premature babies. The company's primary product, NEOLA, provides real-time alerts for life-threatening complications by measuring lung volume changes and oxygen concentration. Neola Medical targets neonatal intensive care units as its key market segment, serving healthcare providers who require advanced monitoring solutions for premature infants. The firm's revenue model relies on selling the NEOLA device and associated technology to hospitals and medical facilities specializing in neonatal care. The company's business concept centers on the commercialization of its medical technology product for continuous lung monitoring, leveraging the GASMAS (Gas in Scattering Media Absorption Spectroscopy) technology. Neola Medical focuses on the neonatal intensive care market segment, where its device offers continuous monitoring capabilities that address critical needs in premature infant care. The primary purpose of the NEOLA device is to support neonatal intensive care through real-time monitoring and alerts for complications. Neola Medical AB's revenue streams come from the sale of the NEOLA medical device and its underlying technology to healthcare institutions. The company targets neonatal intensive care units as its primary customer segment, focusing on hospitals and medical facilities that provide specialized care for premature babies. The firm's business model is built around the commercialization of its patented GASMAS technology through the NEOLA device, which addresses specific monitoring needs in neonatal care.